文献速递骨质疏松与代谢性骨病

罗莫佐单抗与特立帕肽序贯阿仑膦酸治疗日本严重绝经后骨质疏松的成本效果

Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan.
PubMed 文献 · Osteoporos Int · 2021-03-27

本研究采用马尔可夫模型,评估罗莫佐单抗1年序贯阿仑膦酸与特立帕肽2年序贯阿仑膦酸(总疗程5年)治疗日本既往接受双膦酸盐的严重绝经后骨质疏松女性的成本效果。结果显示,罗莫佐单抗/阿仑膦酸较特立帕肽/阿仑膦酸每例患者节省5134美元,并多获得0.045个质量调整生命年(QALY)。

要点

  • 罗莫佐单抗/阿仑膦酸较特立帕肽/阿仑膦酸每例节省5134美元且多获0.045 QALY
  • 基础病例结果经情景分析和概率敏感性分析验证稳健
  • 研究基于骨密度优势转化为骨折相对风险的荟萃回归关系

核心结论

  • 罗莫佐单抗/阿仑膦酸较特立帕肽/阿仑膦酸产生更大健康获益且总成本更低。

研究设计与样本

  • 采用马尔可夫模型,模拟平均年龄78岁、T值≤-2.5且有既往脆性骨折的女性队列终生 horizon。
  • 比较罗莫佐单抗1年与特立帕肽2年,均序贯阿仑膦酸至总疗程5年,从日本医疗系统视角分析,贴现率2%/年。

主要发现

  • 基础病例显示罗莫佐单抗/阿仑膦酸较特立帕肽/阿仑膦酸每例患者减少成本5134美元(2020年美元)。
  • 罗莫佐单抗/阿仑膦酸较特立帕肽/阿仑膦酸每例患者多获得0.045个QALY。
  • 情景分析和概率敏感性分析确认结果对模型假设和输入的不确定性稳健。

关键数值与推荐

  • 罗莫佐单抗1年序贯阿仑膦酸与特立帕肽2年序贯阿仑膦酸,总治疗时长均为5年。
  • 骨密度优势通过骨质疏松治疗试验的荟萃回归关系转化为骨折相对风险。

临床怎么用

  • 对于日本既往接受双膦酸盐的严重绝经后骨质疏松女性,罗莫佐单抗/阿仑膦酸方案可能更具成本效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: This study assessed the cost effectiveness of romosozumab versus teriparatide, both sequenced to alendronate, for the treatment of severe postmenopausal osteoporosis in Japan, using bone mineral density (BMD) efficacy data. Results show that romosozumab/alendronate produces greater health benefits at a lower cost than teriparatide/alendronate. INTRODUCTION: This study aims to assess the cost effectiveness of romosozumab versus teriparatide, both sequenced to alendronate, for the treatment of severe postmenopausal osteoporosis in Japanese women previously treated with bisphosphonates. METHODS: A Markov model was used to assess the relative cost effectiveness of 1 year of romosozumab versus 2 years of teriparatide, both sequenced to alendronate for a total treatment duration of 5 years. Outcomes for a cohort of women with a mean age of 78 years, a T-score ≤-2.5 and a previous fragility fracture were simulated over a lifetime horizon. The analysis was conducted from the perspective of the Japanese healthcare system and used a discount rate of 2% per annum. To inform relative fracture incidence, the bone mineral density (BMD) advantage of romosozumab over teriparatide was translated into relative risks of fracture, using relationships provided by a meta-regression of osteoporosis therapy trials. Outcomes were assessed in terms of lifetime costs (2020 US dollars) and quality-adjusted life years (QALYs). RESULTS: Base case results showed that, compared with teriparatide/alendronate, romosozumab/alendronate reduced costs by $5134 per patient and yielded 0.045 additional QALYs. Scenario analyses and probabilistic sensitivity analysis confirmed that results are robust to uncertainty in model assumptions and inputs. CONCLUSION: Results show that romosozumab/alendronate produces greater health benefits at a lower total cost than teriparatide/alendronate.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Hagino H, Tanaka K, Silverman S, et al. Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan. Osteoporos Int. 2021. PMID: 33772328. doi:10.1007/s00198-021-05927-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。